Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin.

Autor: Mittal K; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Cooper GW; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Lee BP; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Su Y; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Skinner KT; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Shim J; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Jonus HC; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Kim WJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Doshi M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Almanza D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kynnap BD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Christie AL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Yang X; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Cowley GS; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Leeper BA; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Morton CL; Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA., Dwivedi B; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Lawrence T; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Rupji M; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Keskula P; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Meyer S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Clinton CM; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bhasin M; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Crompton BD; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Tseng YY; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Boehm JS; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ligon KL; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Root DE; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Murphy AJ; Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA., Weinstock DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Merck & Co., Rahway, NJ, USA., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Spangle JM; Winship Cancer Institute, Emory University, Atlanta, GA, USA.; Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA., Rivera MN; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Mullen EA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Stegmaier K; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Goldsmith KC; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. william_hahn@dfci.harvard.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. william_hahn@dfci.harvard.edu., Hong AL; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. andrew.hong2@emory.edu.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA. andrew.hong2@emory.edu.; Winship Cancer Institute, Emory University, Atlanta, GA, USA. andrew.hong2@emory.edu.

Publikováno v: Communications biology [Commun Biol] 2024 Apr 08; Vol. 7 (1), pp. 426. Date of Electronic Publication: 2024 Apr 08.

A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.

Autor: Cash T; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.; Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, Georgia, USA., Jonus HC; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA., Tsvetkova M; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Beumer JH; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Sadanand A; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA., Lee JY; Laney Graduate School Cancer Biology Program, Emory University, Atlanta, Georgia, USA., Henry CJ; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.; Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, Georgia, USA.; Laney Graduate School Cancer Biology Program, Emory University, Atlanta, Georgia, USA., Aguilera D; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA., Harvey RD; Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, Georgia, USA.; Department of Hematology/Medical Oncology and Pharmacology, Emory University School of Medicine, Atlanta, Georgia, USA., Goldsmith KC; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.; Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, Georgia, USA.; Laney Graduate School Cancer Biology Program, Emory University, Atlanta, Georgia, USA.

Publikováno v: Pediatric blood & cancer [Pediatr Blood Cancer] 2023 Aug; Vol. 70 (8), pp. e30405. Date of Electronic Publication: 2023 May 09.

Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials.

Autor: Jonus HC; Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA, USA., Burnham RE; Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA, USA., Ho A; Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA, USA., Pilgrim AA; Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Shim J; Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA, USA.; Division of Pediatric Hematology/Oncology, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA., Doering CB; Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA, USA., Spencer HT; Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Goldsmith KC; Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute, Emory University, Atlanta, GA, USA.; Division of Pediatric Hematology/Oncology, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.

Publikováno v: Oncoimmunology [Oncoimmunology] 2022 Mar 26; Vol. 11 (1), pp. 2057012. Date of Electronic Publication: 2022 Mar 26 (Print Publication: 2022).

YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma.

Autor: Shim J; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.; Aflac Cancer and Blood Disorders Center at the Children's Healthcare of Atlanta, Atlanta, Georgia., Lee JY; Cancer Biology Program, Laney Graduate School, Emory University, Atlanta, Georgia., Jonus HC; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia., Arnold A; Neuroscience Institute, Georgia State University, Atlanta, Georgia., Schnepp RW; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.; Aflac Cancer and Blood Disorders Center at the Children's Healthcare of Atlanta, Atlanta, Georgia.; Cancer Biology Program, Laney Graduate School, Emory University, Atlanta, Georgia., Janssen KM; University of Alabama School of Medicine, Birmingham, Alabama., Maximov V; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia., Goldsmith KC; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia. kgoldsm@emory.edu.; Aflac Cancer and Blood Disorders Center at the Children's Healthcare of Atlanta, Atlanta, Georgia.; Cancer Biology Program, Laney Graduate School, Emory University, Atlanta, Georgia.

Publikováno v: Cancer research [Cancer Res] 2020 Nov 01; Vol. 80 (21), pp. 4741-4753. Date of Electronic Publication: 2020 Sep 08.

Development of an IPRP-LC-MS/MS method to determine the fate of intracellular thiamine in cancer cells.

Autor: Kim J; Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, The University of Georgia, Athens, GA 30602-2352, United States., Jonus HC; Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, The University of Georgia, Athens, GA 30602-2352, United States., Zastre JA; Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, The University of Georgia, Athens, GA 30602-2352, United States., Bartlett MG; Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, The University of Georgia, Athens, GA 30602-2352, United States. Electronic address: mgbart@uga.edu.

Publikováno v: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences [J Chromatogr B Analyt Technol Biomed Life Sci] 2019 Aug 15; Vol. 1124, pp. 247-255. Date of Electronic Publication: 2019 Jun 05.